What are effective medication strategies that can be added to an antipsychotic drug treatment to improve the suboptimally responsive global or specific symptom domains among adults with schizophrenia?
In this overview of methodologically sound meta-analyses, 14 combination strategies significantly improved the overall symptoms of schizophrenia compared with antipsychotic monotherapy. Although the meta-analytically based recommendation to use a given combination strategy was correlated with the effect sizes favoring the combination treatment, these effect sizes were inversely correlated with the frequently low quality of the meta-analyzed trials, seriously lowering the confidence in the affirmative recommendation of any combination strategy.
Based on a review of the meta-analytic evidence, aided by a structured evaluation of the quality of meta-analyzed studies, none of the 42 combinations of an antipsychotic drug treatment with a second psychotropic medication had consistent support for its recommendation for treating an unselected population with schizophrenia.
Limited treatment responses in schizophrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic medication. A comprehensive evaluation of the efficacy of multiple medication combinations is missing.
To summarize and compare the meta-analytically determined efficacy of pharmacologic combination strategies of antipsychotic drugs in adults with schizophrenia.
Systematic search of PubMed and PsycInfo until May 13, 2016.
Meta-analyses of randomized clinical trials comparing the efficacy of antipsychotic drugs combined with other antipsychotic or nonantipsychotic medications vs placebos or antipsychotic monotherapy among adults with schizophrenia.
Data Extraction and Synthesis
Independent reviewers extracted the data and assessed the quality of the methods of the included meta-analyses using A Measurement Tool to Assess Systematic Reviews (AMSTAR), adding 6 new items to rate their quality. Effect sizes, expressed as standardized mean difference /Hedges g or risk ratio, were compared separately for combinations with any antipsychotic drug and for combinations with clozapine.
Main Outcomes and Measures
The primary outcome was total symptom reduction. Secondary outcomes included positive and negative symptoms, treatment recommendations by authors, study-defined inefficacies, cognitive and depressive symptoms, discontinuation of treatment because of any cause, and inefficacies or intolerabilities.
Of 3397 publications, 29 meta-analyses testing 42 combination strategies in 381 individual trials and among 19 833 participants were included. For total symptom reductions, 32 strategies that augmented any antipsychotic drug and 5 strategies that augmented clozapine were examined. Fourteen combination treatments outperformed controls (standard mean difference/Hedges g, −1.27 [95% CI, −2.35 to −0.19] to −0.23 [95% CI, −0.44 to −0.02]; P = .05). No combination strategies with clozapine outperformed controls. The quality of the methods of the meta-analyses was generally high (mean score, 9 of a maximum score of 11) but the quality of the meta-analyzed studies was low (mean score, 2.8 of a maximum score of 8). Treatment recommendations correlated with the effect size (correlation coefficient, 0.22; 95% CI, 0.35-0.10; P < .001), yet effect sizes were inversely correlated with study quality (correlation coefficient, −0.06; 95% CI, 0.01 to −0.12; P = .02).
Conclusions and Relevance
Meta-analyses of 21 interventions fully or partially recommended their use, with recommendations being positively correlated with the effect sizes of the pooled intervention. However, the effect sizes were inversely correlated with meta-analyzed study quality, reducing confidence in these recommendations. Higher-quality trials and patient-based meta-analyses are needed to determine whether subpopulations might benefit from combination treatment, as no single strategy can be recommended for patients with schizophrenia based on the current meta-analytic literature.
Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in SchizophreniaSystematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry. Published online May 17, 2017. doi:10.1001/jamapsychiatry.2017.0624